Kevin P Starr

Kevin P Starr has an estimated net worth of $44.2 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., Fulcrum Therapeutics, Inc., Revolution Medicines, Inc., PLIANT THERAPEUTICS, INC., Editas Medicine, Inc., Voyager Therapeutics, Inc., Blueprint Medicines Corp, Nurix Therapeutics, Inc., Relay Therapeutics, Inc., Foundation Medicine, Inc., Decibel Therapeutics, Inc., Eleven Biotherapeutics, Inc., CytomX Therapeutics, Inc., Jounce Therapeutics, Inc., Global Blood Therapeutics, Inc., ALNYLAM PHARMACEUTICALS, INC., AGIOS PHARMACEUTICALS INC, CONSTELLATION PHARMACEUTICALS INC, Sage Therapeutics, Inc., MyoKardia Inc, Neon Therapeutics, Inc., ZAFGEN, INC., Allena Pharmaceuticals, Inc., and HUMAN GENOME SCIENCES INC.

2015 was Kevin P Starr's most active year for acquiring shares with 19 total transactions. Kevin P Starr's most active month to acquire stocks was the month of May. 2014 was Kevin P Starr's most active year for disposing of shares, totalling 13 transactions. Kevin P Starr's most active month to dispose stocks was the month of August. 2015 saw Kevin P Starr paying a total of $1,979,335.78 for 713,729 shares, this is the most they've acquired in one year. In 2018 Kevin P Starr cashed out on 59,000 shares for a total of $9,962,249.90, their largest year based on trade value.